Combination ophthalmic decongestant and NSAID

This page covers all Combination ophthalmic decongestant and NSAID drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac), Alpha-1 adrenergic receptor.

Targets

Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac) · Alpha-1 adrenergic receptor

Marketed (3)

• Phenylephrine 1.0%/ Ketorolac 0.3% · University of Florida · Ophthalmology
  This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects.
• Saline solution, 0.6% · Novaliq GmbH · Ophthalmology
  Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue.
• Visine® for Contacts® · Merck Sharp & Dohme LLC · Ophthalmology
  Visine for Contacts is a decongestant eye drop that constricts blood vessels in the eye to reduce redness and irritation.

Patent intelligence

• ophthalmic decongestant patent landscape — aggregated cliff calendar, attackable patents, originator estates